Peter Borchmann
TH Köln - University of Applied Sciences(DE)University of Cologne(DE)Düsseldorf University Hospital(DE)Integrated Oncology (United States)(US)German Inflammatory Bowel Diseases Study Group(DE)Nordic Lymphoma Group(DK)Lungenklinik Köln-Merheim(DE)Centrum für Integrierte Onkologie(DE)University Hospital Cologne(DE)Heinrich Heine University Düsseldorf(DE)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Lung Cancer Treatments and Mutations, CAR-T cell therapy research, CNS Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma(2018)3,936 cited
- → Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma(2010)910 cited
- → Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy(2012)667 cited
- → Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial(2012)622 cited
- → Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study(2021)537 cited
- → Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial